LiquidCell Dx Announces Nature Paper on Tumor Microenvironment and Therapy Response
LiquidCell Dx has published a paper in Nature that supports the development of LiquidTME, a blood-based assay for profiling the tumor microenvironment. The research highlights significant features of the tumor microenvironment, particularly concerning immune cells and other cell types, and their functions in predicting therapy response.
SAN CARLOS, Calif.–(BUSINESS WIRE)–LiquidCell Dx, a next generation cancer diagnostics company, today announced publication in Nature of critical research underpinning the development of LiquidTME, its blood-based assay for tumor microenvironment profiling. The paper defines highly recurrent and clinically relevant features of the tumor microenvironment, including the immune cells, but also the many other cell types present in a tumor and their key functions, and demonstrates that they can be